**Q2:** Title of your recommendation  
Access to HIV PrEP for under 18 years old

**Q3:** Please provide a description of your proposed recommendation  
It is very difficult for young people to access PrEP without their parents consent, due to insurance issues and organizational protocols.

**Q4:** For which goal outlined in the Governor’s plan to end the epidemic in New York State does this recommendation apply? (Select all that apply)  
Facilitating access to Pre-Exposure Prophylaxis (PrEP) for high-risk persons to keep them HIV negative

**Q5:** This recommendation should be considered by the following Ending the Epidemic Task Force Committee (Select all that apply)  
Prevention Committee: Develop recommendations for ensuring the effective implementation of biomedical advances in the prevention of HIV, (such as the use of Truvada as pre-exposure prophylaxis (PrEP)); for ensuring access for those most in need to keep them negative; and for expansion of syringe exchange, expanded partner services, and streamlined HIV testing by further implementing the universal offer of HIV testing in primary care, among others. The Committee will focus on continuing innovative and comprehensive prevention and harm reduction services targeted at key high risk populations, as well as grant-funded services that engage in both secondary and primary prevention.

**Q6:** Does this recommendation require a change to an existing policy or program, or the creation of a new policy or program?  
Unknown

**Q7:** Would implementation of this recommendation be permitted under current laws or would a statutory change be required?  
Unknown

**Q8:** Is this recommendation something that could feasibly be implemented in the short-term (within the next year) or long-term (within the next three to six years)?  
Unknown
**Q9: What are the perceived benefits of implementing this recommendation?**

More preventative tools for high risk group and potentially an opportunity to engage HIV neg individuals in more routine care.

**Q10: Are there any concerns with implementing this recommendation that should be considered?**  
Respondent skipped this question

**Q11: What is the estimated cost of implementing this recommendation and how was this estimate calculated?**  
Respondent skipped this question

**Q12: What is the estimated return on investment (ROI) for this recommendation and how was the ROI calculated?**  
Respondent skipped this question

**Q13: Who are the key individuals/stakeholders who would benefit from this recommendation?**  
Respondent skipped this question

**Q14: Are there suggested measures to accompany this recommendation that would assist in monitoring its impact?**  
Respondent skipped this question

**Q15: This recommendation was submitted by one of the following**

Ending the Epidemic Task Force member